Generation Bio Inc. (GBIO) News

Generation Bio Inc. (GBIO): $20.39

-0.37 (-1.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GBIO News Items

GBIO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GBIO News Highlights

  • 500 - Internal server error
  • Over the past 6 days, the trend for GBIO's stories per day has been choppy and unclear. It has oscillated between 3 and 4.
  • RES, BIO and GENE are the most mentioned tickers in articles about GBIO.

Latest GBIO News From Around the Web

Below are the latest news stories about Generation Bio Co that investors may wish to consider to help them evaluate GBIO as an investment opportunity.

Generation Bio Announces Plan to Scale Next-Generation Rapid Enzymatic Manufacturing Process Across Portfolio and Provides Pipeline Update

Company to transition all portfolio programs to rapid enzymatic synthesis (RES), enabling improved quality, scale and speed of closed-ended DNA manufacturing Lease agreement signed to build an in-house RES manufacturing facility providing cGMP capacity for and internal control over clinical and initial commercial supply IND submission for hemophilia A now planned for 2023; factor VIII expression

Wallstreet:Online | July 14, 2021

Generation Bio to Present at William Blair Biotech Focus Conference

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the William Blair Biotech Focus Conference 2021 on Thursday, July 15, at 9:00 a.m. ET.

Intrado Digital Media | July 8, 2021

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | June 19, 2021

Generation Bio to Present at the JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the JMP Securities Life Sciences Conference on Wednesday, June 16, at 11:30 a.m. ET.

Intrado Digital Media | June 9, 2021

Generation Bio to Present at the Jefferies Virtual Healthcare Conference

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, announced today that Geoff McDonough, M.D., president and chief executive officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 11:30 a.m. ET.

BioSpace | May 26, 2021

William Blair Initiates a Buy Rating on Generation Bio (GBIO)

William Blair analyst Raju Prasad initiated coverage with a Buy rating on Generation Bio (GBIO) today. The companys shares closed last Wednesday at The post William Blair Initiates a Buy Rating on Generation Bio (GBIO) appeared first on Smarter Analyst .

Smarter Analyst | May 13, 2021

Private Advisor Group LLC Takes $218,000 Position in Generation Bio Co. (NASDAQ:GBIO)

Private Advisor Group LLC purchased a new position in shares of Generation Bio Co. (NASDAQ:GBIO) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,646 shares of the companys stock, valued at approximately $218,000. Other institutional investors have also modified their holdings of the []

Dakota Financial News | May 12, 2021

Generation Bio Presents Preclinical Data Demonstrating Broad Potential of Gene Therapy Platform at ASGCT and Reports First Quarter Financial Results

Generation Bio Co. (Nasdaq: GBIO), an innovative genetic medicines company creating a new class of non-viral gene therapy, today reported data from multiple digital presentations during the ongoing 24th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting as well as first quarter 2021 financial results

BioSpace | May 11, 2021

Generation Bio Co. (NASDAQ:GBIO) Given Consensus Recommendation of Buy by Brokerages

Shares of Generation Bio Co. (NASDAQ:GBIO) have been given a consensus rating of Buy by the seven ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokers []

Dakota Financial News | May 11, 2021

Needham Assigns a Buy Rating on Generation Bio (GBIO)

Needham analyst Gil Blum assigned a Buy rating to Generation Bio (GBIO) today and set a price target of $50.00. The post Needham Assigns a Buy Rating on Generation Bio (GBIO) appeared first on Smarter Analyst .

Smarter Analyst | May 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5616 seconds.